Jasper gains 11% on data for briquilimab in urticaria

seekingalpha10-15

Shares of Jasper (NASDAQ:JSPR) closed 11% higher Monday after the company released positive data from a Phase 1b/2a study of subcutaneous briquilimab in patients with chronic inducible urticaria, or ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475347686?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1175270464/image_1175270464.jpg","is_english":true,"pubTime":"2024-10-15 05:31","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2475347686","market":"sg","top_or_hot":-1,"title":"Jasper gains 11% on data for briquilimab in urticaria","media":"seekingalpha","content":"<div>\n<p>Shares of Jasper (NASDAQ:JSPR) closed 11% higher Monday after the company released positive data from a Phase 1b/2a study of subcutaneous briquilimab in patients with chronic inducible urticaria, or ...</p>\n\n<a href=\"https://seekingalpha.com/news/4158360-jasper-gains-on-data-for-briquilimab-in-urticaria\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jasper gains 11% on data for briquilimab in urticaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJasper gains 11% on data for briquilimab in urticaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 05:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4158360-jasper-gains-on-data-for-briquilimab-in-urticaria><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Jasper (NASDAQ:JSPR) closed 11% higher Monday after the company released positive data from a Phase 1b/2a study of subcutaneous briquilimab in patients with chronic inducible urticaria, or ...</p>\n\n<a href=\"https://seekingalpha.com/news/4158360-jasper-gains-on-data-for-briquilimab-in-urticaria\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JSPR","symbol_name":"Jasper Therapeutics","start_time":0,"source_url":"https://seekingalpha.com/news/4158360-jasper-gains-on-data-for-briquilimab-in-urticaria","article_id":"2475347686","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1175270464/image_1175270464.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475347686","pubTimestamp":1728941467,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Jasper  closed 11% higher Monday after the company released positive data from a Phase 1b/2a study of subcutaneous briquilimab in patients with chronic inducible urticaria, or CIndU. Patients enrolled in the study had one of two subtypes of CIndU, cold urticaria or symptomatic dermographism.   The study showed 14, or 93%, of the 15 patients enrolled in both dose cohorts of the study achieved a clinical response within the six-week preliminary analysis period following administration. Ten, or 83%, of the 12 patients enrolled in the 120mg dose cohort showed a complete response, according to a statement. Jasper plans to present full data from the study, called SPOTLIGHT, in the first half of 2025. Other companies working on treatments for urticaria include Acelyrin , Allakos , Celldex , ARS Pharmaceuticals , Regeneron  and Sanofi .","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JSPR":"Jasper Therapeutics","BK4139":"生物科技"},"translate_title":"Jasper因briquilimab治疗荨麻疹的数据而上涨11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JSPR":0.9},"content_text":"Shares of Jasper (NASDAQ:JSPR) closed 11% higher Monday after the company released positive data from a Phase 1b/2a study of subcutaneous briquilimab in patients with chronic inducible urticaria, or CIndU. Patients enrolled in the study had one of two subtypes of CIndU, cold urticaria or symptomatic dermographism.   The study showed 14, or 93%, of the 15 patients enrolled in both dose cohorts of the study achieved a clinical response within the six-week preliminary analysis period following administration. Ten, or 83%, of the 12 patients enrolled in the 120mg dose cohort showed a complete response, according to a statement. Jasper plans to present full data from the study, called SPOTLIGHT, in the first half of 2025. Other companies working on treatments for urticaria include Acelyrin (SLRN), Allakos (ALLK), Celldex (CLDX), ARS Pharmaceuticals (SPRY), Regeneron (REGN) and Sanofi (SNY).","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475347686"}